ScoreComparison
Why is RaQualia Pharma, Inc. ?
1
Poor Management Efficiency with a low ROE of 4.41%
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 62.14
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 62.14
- The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds
3
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%
4
With a growth in Net Profit of 4227.77%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- NET SALES(HY) At JPY 2,470.92 MM has Grown at 45.05%
- NET PROFIT(HY) Higher at JPY 632.34 MM
- ROCE(HY) Highest at 0.77%
5
With ROE of 0.72%, it has a attractive valuation with a 1.43 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -2.26%, its profits have risen by 113% ; the PEG ratio of the company is 1.8
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to RaQualia Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is RaQualia Pharma, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
RaQualia Pharma, Inc.
-18.38%
-0.19
78.64%
Japan Nikkei 225
60.14%
2.04
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.41%
EBIT Growth (5y)
41.24%
EBIT to Interest (avg)
75.61
Debt to EBITDA (avg)
22.67
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.33
Tax Ratio
78.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.90%
ROE (avg)
4.41%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
200
Industry P/E
Price to Book Value
1.43
EV to EBIT
42.13
EV to EBITDA
13.63
EV to Capital Employed
1.57
EV to Sales
2.54
PEG Ratio
1.79
Dividend Yield
0.00%
ROCE (Latest)
3.72%
ROE (Latest)
0.72%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
NET SALES(HY)
At JPY 2,470.92 MM has Grown at 45.05%
NET PROFIT(HY)
Higher at JPY 632.34 MM
ROCE(HY)
Highest at 0.77%
RAW MATERIAL COST(Y)
Fallen by 1.35% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -21.09 %
-12What is not working for the Company
PRE-TAX PROFIT(Q)
At JPY -147.19 MM has Fallen at -1,734.56%
NET PROFIT(Q)
At JPY -214.16 MM has Fallen at -13,225.6%
INTEREST(HY)
At JPY 30.62 MM has Grown at 5.66%
NET SALES(Q)
At JPY 801.99 MM has Fallen at -16.93%
Here's what is working for RaQualia Pharma, Inc.
Debt-Equity Ratio
Lowest at -21.09 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 1.35% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for RaQualia Pharma, Inc.
Pre-Tax Profit
At JPY -147.19 MM has Fallen at -1,734.56%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (JPY MM)
Net Profit
At JPY -214.16 MM has Fallen at -13,225.6%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Net Sales
At JPY 801.99 MM has Fallen at -16.93%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (JPY MM)
Interest
At JPY 30.62 MM has Grown at 5.66%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
